Udink ten Cate Floris E A, ten Hove Christine H, Nix Wendy M L E, de Vries Johanna I P, van de Loosdrecht Arjan A, van Elburg Ruurd M
Subdivision of Neonatology, Department of Pediatrics, VU University Medical Center, Amsterdam, The Netherlands.
Neonatology. 2009;95(1):80-5. doi: 10.1159/000151759. Epub 2008 Sep 12.
Transient neonatal myelosuppression (TNM) is a rare but potentially life-threatening adverse effect of fetal exposure to maternal chemotherapy during pregnancy. We report a case of TNM in a preterm infant born to a mother diagnosed with acute lymphoblastic leukemia during pregnancy. The mother received chemotherapy during the second and third trimester. The neonate was successfully treated with supportive care. In addition, we also conducted a medical literature review and identified another 14 cases of TNM. Although the long-term outcome of these children is not known, short-term survival is relatively good. Prompt recognition and aggressive treatment of infants at risk for TNM is mandatory.
短暂性新生儿骨髓抑制(TNM)是胎儿在孕期暴露于母体化疗药物下罕见但可能危及生命的不良反应。我们报告了一例TNM病例,患儿母亲在孕期被诊断为急性淋巴细胞白血病,患儿为早产儿。母亲在妊娠中期和晚期接受了化疗。该新生儿通过支持治疗成功治愈。此外,我们还进行了医学文献回顾,又发现了14例TNM病例。尽管这些患儿的长期预后尚不清楚,但短期生存率相对较好。对于有TNM风险的婴儿,必须及时识别并积极治疗。